Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 67 | 1111-39-3 |
| Dose | Unit | Route |
|---|---|---|
| 0.20 | mg | O |
| Property | Value | Reference |
|---|---|---|
| BA (Bioavailability) | 70 % | Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H |
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 2.069 | High | 0.82 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 6.776 | High | 0.82 | |
| herg | hERG pIC50 | 4.501 | pIC50 | High | 0.82 |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 30.409 | 10^-6 cm/s | High | 0.82 |
| dh-clint | Dog hepatocyte intrinsic clearance | 5.445 | uL/min/10^6 cells | High | 0.82 |
| dppb | Dog plasma protein binding (% unbound) | 26.060 | % | High | 0.82 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 26.730 | % | High | 0.82 |
| hh-clint | Human hepatocyte intrinsic clearance | 3.126 | uL/min/10^6 cells | High | 0.82 |
| hlm-clint | Human liver microsomal intrinsic clearance | 13.521 | uL/min/mg protein | High | 0.82 |
| hppb | Human plasma protein binding (% unbound) | 26.820 | % | High | 0.82 |
| kinase-safety-class | ACVR2B,CDK5,EIF2AK3,GRK2,ITK,PDK1,PDK2,PDK4,PRKDC | 9 | |||
| mdck-mdr1-bcrp-efflux | MDCK-MDR1-BCRP efflux ratio | 41.495 | Moderate | 0.68 | |
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 12.359 | High | 0.82 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 13.428 | High | 0.82 | |
| mppb | Mouse plasma protein binding (% unbound) | 15.040 | High | 0.82 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 30.339 | High | 0.82 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pld-class | Phospholipidosis risk class (1 = positive, 0 = negative) | 1 | Moderate | 0.68 | |
| pppb | Pig plasma protein binding (% unbound) | 32.120 | % | High | 0.82 |
| rat-kpuu-brain | Rat brain Kpuu | 0.052 | % | Moderate | 0.68 |
| rh-clint | Rat hepatocyte intrinsic clearance | 6.353 | uL/min/10^6 cells | High | 0.82 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 64.640 | % | High | 0.82 |
| rppb | Rat plasma protein binding (% unbound) | 23.400 | % | High | 0.82 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 651.628 | uM | High | 0.82 |
| Date | Agency | Company | Orphan |
|---|---|---|---|
| April 24, 1975 | FDA | NOVARTIS |
None
None
None
None
| Source | Code | Description |
|---|---|---|
| ATC | C01AA01 | CARDIOVASCULAR SYSTEM CARDIAC THERAPY CARDIAC GLYCOSIDES Digitalis glycosides |
| MeSH PA | D000889 | Anti-Arrhythmia Agents |
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D004791 | Enzyme Inhibitors |
| MeSH PA | D020011 | Protective Agents |
| CHEBI has role | CHEBI:35554 | cardiovascular drug |
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Congestive heart failure | indication | 42343007 | DOID:6000 |
| Atrial fibrillation | indication | 49436004 | DOID:0060224 |
None
None
None
None
None
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Sodium/potassium-transporting ATPase | Transporter | INHIBITOR | CHEMBL | CHEMBL |
| ID | Source |
|---|---|
| D06881 | KEGG_DRUG |
| 132871 | RXNORM |
| C0520442 | UMLSCUI |
| CHEBI:53773 | CHEBI |
| CHEMBL3545057 | ChEMBL_ID |
| D000112 | MESH_DESCRIPTOR_UI |
| DB00511 | DRUGBANK_ID |
| 6794 | IUPHAR_LIGAND_ID |
| 792 | INN_ID |
| 0ZV4Q4L2FU | UNII |
| 5284512 | PUBCHEM_CID |
| 000596 | NDDF |
| 7834009 | SNOMEDCT_US |
None